Novel Kidney-Protective Effects Found for BridgeBio's Acoramidis in ATTR-CM
BBIO sits 77% above its 52-week low of $41.8.
Summary
BridgeBio Pharma announced new post-hoc analyses published in *Circulation:Heart Failure*, demonstrating that its approved drug, acoramidis, provides early and sustained direct kidney-protective effects in ATTR-CM patients. These findings, derived from Phase 2 and Phase 3 ATTRibute-CM studies, show a profile consistent with drugs acting directly on the kidney, a benefit not previously observed with other ATTR-CM therapies. This novel data strengthens acoramidis's competitive position and could expand its market potential by addressing a critical comorbidity in ATTR-CM.
At the time of this announcement, BBIO was trading at $74.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $41.80 to $84.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.